UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 150

Sortiert nach

The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS4124-TPS4124

2020

Link zum Volltext

Verfügbarkeit prüfen

International harmonization of diagnostic criteria for HER2 -amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3594-3594

2018

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3508-3508

2015

Link zum Volltext

Verfügbarkeit prüfen

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3636-3636

2013

Link zum Volltext

Verfügbarkeit prüfen

Time course of regorafenib-associated adverse events in the phase III CORRECT study

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.467-467

2013

Link zum Volltext

Verfügbarkeit prüfen

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

Clinical cancer research, 2022-04, Vol.28 (7), p.1302-1312

2022

Link zum Volltext

Verfügbarkeit prüfen

A Multicenter Phase II Study of AMG 337 in Patients with MET -Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET -Amplified Solid Tumors

Clinical cancer research, 2019-04, Vol.25 (8), p.2414-2423

2019

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase 3 study of entrectinib versus crizotinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9141-TPS9141

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3636-TPS3636

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.127-127

2022

Link zum Volltext

Verfügbarkeit prüfen

Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3513-3513

2023

Link zum Volltext

Verfügbarkeit prüfen

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS3631-TPS3631

2023

Link zum Volltext

Verfügbarkeit prüfen

Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS3633-TPS3633

2023

Link zum Volltext

Verfügbarkeit prüfen

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS261-TPS261

2023

Link zum Volltext

Verfügbarkeit prüfen

Reply to E. Hawkes et al

Journal of clinical oncology, 2010-10, Vol.28 (28), p.e532-e533

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3506-3506

2021

Link zum Volltext

Verfügbarkeit prüfen

Genomic landscape of ERBB2/3 alterations in colorectal cancer: Comutations, immuno-oncology biomarkers, and consensus molecular subtype

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.176-176

2022

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS224-TPS224

2022

Link zum Volltext

Verfügbarkeit prüfen

HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3528-3528

2023

Link zum Volltext

Verfügbarkeit prüfen

High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS2675-TPS2675

2023

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3501-3501

2023

Link zum Volltext

Verfügbarkeit prüfen

HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.198-198

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT167-CT167

2021

Link zum Volltext

Verfügbarkeit prüfen

Assessment of HER2 ( ERBB2 ) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3589-3589

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 150

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

ThemaScience & Technology

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(147)

Publikationsform

Artikel
(149)
Tagungsberichte
(1)

Sprache

Englisch
(150)
Japanisch
(7)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Journal Of Clinical Oncology
(95)
Cancer Research
(25)
Clinical Cancer Research
(6)
Blood
(5)
The Lancet
(5)
Cancer
(2)
Nature Medicine
(2)
Annals Of The New York Academy Of Sciences
(1)
Current Opinion In Oncology
(1)
Gastroenterology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

International harmonization of diagnostic criteria for HER2 -amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method

Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial

Time course of regorafenib-associated adverse events in the phase III CORRECT study

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

A Multicenter Phase II Study of AMG 337 in Patients with MET -Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET -Amplified Solid Tumors

A randomized phase 3 study of entrectinib versus crizotinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets)

Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study

Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study

Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer

Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial)

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress

Reply to E. Hawkes et al

Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial

Genomic landscape of ERBB2/3 alterations in colorectal cancer: Comutations, immuno-oncology biomarkers, and consensus molecular subtype

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02)

HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS

High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study

HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial

Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies

Assessment of HER2 ( ERBB2 ) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC)

Aktive Filter

Suchergebnisse filtern